[Re-evaluation of barbexaclone in 20 epileptic patients].
The clinically observed results in 20 patients treated with barbexaclone for a period of 2 1/2 years are reported. Therapeutic efficiency as well as side effects are discussed. The authors draw attention to the fact that there was a concomitant improvement in the behaviour of some patients and a diminution of maintainence dosage in relation to a previously published trial.
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010634:Phenobarbital / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011437:Propylamines / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012640:Seizures / Q000188:drug therapy*
D000927:Anticonvulsants; D011437:Propylamines; C011019:barbexaclone; D010634:Phenobarbital
Reavaliação do barbexaclone em 20 pacientes epiléticos.